LENZ Therapeutics, Inc. posted a wider-than-expected loss in its fourth quarter of 2025, reflecting the cash-intensive nature of its commercial launch. The ophthalmology company reported a GAAP loss of $1.16 per share, missing analyst estimates that had called for a loss of $0.99 per share. The miss represented a 17.1% wider loss than the Street had anticipated.
The company generated $1.6M in revenue for the quarter as it continues early commercialization efforts for its presbyopia treatment. LENZ posted a net loss of $35.9M for the three-month period, underscoring the significant investment required to establish market presence in the competitive eye care space.
The quarter showed traction in physician adoption and patient uptake metrics. LENZ reported that 20,000 paid prescriptions were filled during the period, while the company’s prescriber base expanded to 6,500 unique prescribers at quarter end. These figures provide a snapshot of the company’s penetration into the ophthalmology and optometry communities as it works to drive awareness of its novel therapeutic approach to age-related near vision loss.
A detailed analysis of LENZ Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.